#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Immune-mediated myasthenia gravis Waldenstrom's macroglobulinaemia Congenital ectodermal dysplasia Uterine leiomyosarcoma Antithrombin III deficiency Dementia Alzheimer's type Lung adenocarcinoma Porphyria non-acute Acute on chronic liver failure Myocarditis Anti-myelin-associated glycoprotein associated polyneuropathy Lymphatic malformation Colorectal cancer metastatic Congenital nephrogenic diabetes insipidus Biliary neoplasm More trials…

    Learn about Rare Diseases

    VEXAS syndrome – Basic Information Haemophilia A without inhibitors – Trials in Disease Malignant fibrous histiocytoma – Life with Disease Rhabdomyosarcoma recurrent – Treatment Rosai-Dorfman syndrome – Treatment Vascular malformation – Basic Information Carcinoid syndrome – Basic Information Ewing’s sarcoma metastatic Waldenstrom’s macroglobulinaemia – Diagnostics Von Willebrand’s disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    ULEFNERSEN HYDROXYCHLOROQUINE Efanesoctocog Alfa X-396 Clodronate Disodium Cefalexin Monohydrate HUMAN COAGULATION FACTOR XIII Savolitinib Paroxetine Istaroxime Batoprotafib Dasatinib Avatrombopag Abiraterone Belzutifan Pemetrexed Disodium Tolu Balsam Promazine Hydrochloride D-Camphor Dabigatran Etexilate More therapies…

    Learn about Your Condition

    Cutaneous T-cell lymphoma Ventricular extrasystoles Mitral valve prolapse Large cell lung cancer stage 0 Cardiac sarcoidosis Peritoneal cancer index Mucous membrane pemphigoid Angiosarcoma metastatic Paraesthesia Obliterative bronchiolitis Carotid artery occlusion Anaplastic thyroid cancer Erosive oesophagitis Chondrosarcoma metastatic Testis cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Warminsko-Mazurskie Centrum Chorob Pluc W Olsztynie…

Warminsko-Mazurskie Centrum Chorob Pluc W Olsztynie

Ul. Jagiellonska Nr 78, Olsztyn, 10-357, Poland

Want to learn more about this study or check if you can participate? Contact us.

  • Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Buclizine Hydrochloride
    • Carboplatin
    • Cisplatin
    Austria Belgium Czechia France Germany Greece +7

  • A Study of Amivantamab and Lazertinib for Adults with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated Drugs:
    • Amivantamab
    • Lazertinib
    Belgium Finland France Germany Greece Italy +3

  • A Study of MK-1084 and Drug Combination Versus Pembrolizumab and Chemotherapy for Adults with Advanced Lung Cancer with KRAS G12C Mutation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Mk-1084
    Austria Belgium France Germany Greece Hungary +5

  • Study comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • GSK5764227
    • Topotecan
    Bulgaria Finland France Germany Greece Hungary +7

  • Study of THIO and cemiplimab compared to chemotherapy in patients with advanced non-small cell lung cancer who have received two previous treatments

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage III
    • Non-small cell lung cancer
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • 2-Amino-9-((2R,4R,5R)-4-Hydroxy-5-(Hydroxymethyl) Tetrahydrofuran-2-Yl)-1,4,5,9-Tetrahydro-6H-Purine-6-Thione
    • Vinorelbine
    • Cemiplimab
    Hungary Poland Portugal Romania Spain

  • Study comparing QL2107 and pembrolizumab in patients with resected non-small cell lung cancer receiving adjuvant therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Pembrolizumab
    Greece Hungary Poland Romania Spain

  • Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • BNT327
    • Carboplatin
    • Paclitaxel
    Belgium Bulgaria France Germany Hungary Italy +3

  • Study on the Safety and Effectiveness of Osimertinib and Datopotamab Deruxtecan for Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Datopotamab Deruxtecan
    • Osimertinib
    France Germany Italy Poland Spain

  • Study of Pembrolizumab and V940 for Treating Non-Small Cell Lung Cancer in Patients with Resectable Stage II to IIIB (N2) Not Achieving Complete Response

    Recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Gemcitabine Hydrochloride
    Belgium Bulgaria Finland France Germany Greece +8

  • Study Comparing MK-2870 and Pembrolizumab Combination to Pembrolizumab Alone for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Betamethasone Sodium Phosphate Ph. Eur
    • Caffeine
    • Acetylsalicylic Acid
    Czechia Denmark France Germany Italy The Netherlands +3
Previous Page
1 2 3 4 … 8
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!